Hologic acquired Gen-Probe for $3.7 billion
On Apr. 30, 2012, Hologic announced the acquisition of San Diego-based Gen-Probe, a molecular diagnostics company, for $3.7…
-
-
Treatment outcomes in black and white children with cancer was published
On Apr. 30, 2012, “Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database…
-
Biotechnology | Diagnostics | Disease | Medicine | Non-Profit Research | Oncology | Therapeutics | Women's Health
The University of Minnesota Masonic Children’s Hospital opened a new, innovative building for mothers and children
On Apr. 30, 2011, The University of Minnesota Masonic Children’s Hospital opened a new, innovative building for mothers…
-
National Women and Girls HIV/AIDS Awareness Day was established
On Mar. 10, 2010, National Women and Girls HIV/AIDS Awareness Day (NWGHAAD) was established as a nationwide initiative…
-
Siteman Cancer Center received NCI SPORE grant to study endometrial cancer
On Mar. 5, 2010, the National Cancer Institute (NCI) announced that it had awarded the Siteman Cancer Center…
-
FDA approved Cervarix, GlaxoSmithKline’s cervical cancer vaccine
On Oct. 16, 2009, GlaxoSmithKline announced the U.S. Food and Drug Administration (FDA) had approved Cervarix [Human papillomavirus…
-
OHSU Cancer Institute received $5 million gift to establish state-of-the-art research laboratories
On Feb. 20, 2008, Lori and Jen-Hsun Huang of Los Altos Hills, California, announced a $5 million gift…
-
Evestra was spun-off as a private company from the Texas Biomed Department of Organic Chemistry
In 2008, Evestra was spun-off as a private biopharmaceutical company from the Texas Biomed Department of Organic Chemistry….
-
Biotechnology | Diagnostics | Disease | Non-Profit Research | Oncology | Radiology | Therapeutics | Women's Health
Seattle Cancer Care Alliance introduced the Mammovan, making digital mammography more accessible
In 2008, the Seattle Cancer Care Alliance introduced the Mammovan, making digital mammography more accessible to women throughout…
-
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The Breast Cancer Research Stamp Reauthorization Act extended through December 31, 2011
On Dec. 12, 2007, the Breast Cancer Research Stamp Reauthorization Act extended through Dec. 31, 2011, provisions requiring…
-
National Cancer Institute developed more accurate method of estimating invasive breast cancer risk in African americans
On Nov. 27, 2007, a new National Cancer Institute (NCI) model for calculating invasive breast cancer risk, called…
-
Biotechnology | Disease | FDA | Oncology | Therapeutics | Women's Health
The FDA approved Eli Lilly and Company’s osteoporosis drug, Evista, to reduce the risk of invasive breast cancer
On Sept. 14, 2007, the U.S. Food and Drug Administration (FDA) announced it had approved Eli Lilly’s osteoporosis…
-
National Breast and Cervical Cancer Act allowed states federal waivers to spend a greater share of funds on underserved women
On Apr. 20, 2007, President Bush signed critical legislation into law today to expand a successful program that…
-
MRI detected cancers in the opposite breast of women newly diagnosed with breast cancer
On Mar. 28, 2007, Magnetic Resonance Imaging (MRI) scans of women who were diagnosed with cancer in one…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Therapeutics | Women's Health
FDA approved trastuzumab for use with other drugs in adjuvant treatment of women with early-stage, node-positive, HER2-overexpressing breast cancer
On Nov. 16, 2006, the U.S. Food and Drug Administration (FDA) approved Genentech’s trastuzumab (Herceptin) for use with…
-
Biotechnology | Diagnostics | Disease | Genomics | NIH | Oncology | Therapeutics | Women's Health
NIH announced two integral components of the Cancer Genome Atlas Pilot Project
On Oct. 16, 2006, the Cancer Genome Atlas program, created by National Cancer Institute and the National Human…
-
Eli Lilly and Company’s Gemzar was approved for use in the treatment of women living with recurrent ovarian cancer
On Jul. 17, 2006, Eli Lilly and Company’s Gemzar was approved by the U.S. Food and Drug Administration (FDA) for…
-
Personalized treatment trial for breast cancer was launched
On May 23, 2006, the Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, was launched to examine…
-
Biotechnology | Disease | NIH | Oncology | Therapeutics | Women's Health
Osteoporosis drug shown to be as effective as Tamoxifen in preventing invasive breast cancer
On Apr. 17, 2006, the National Cancer Institute (NCI) announced initial results of the Study of Tamoxifen and…
-
NCI launched TAILORx trial to determine whether gene expression patterns in early-stage breast cancer can distinguish women at high risk of recurrence
In 2006, the National Cancer Institute (NCI) launched the TAILORx trial to determine whether gene expression patterns in…
-
Studies validated a new test can predict risk of breast cancer recurrence in a sizable group of patients
On Dec. 7, 2005, results from several studies presented at the San Antonio Breast Cancer Symposium validated that…
-
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The 2-Year Extension of Postage Stamp for Breast Cancer Research (PL 109-100) was extended
On Nov. 11, 2005, the U.S. Congress authorized the 2-year extension of Postage Stamp for Breast Cancer Research…
-
Preliminary results from clinical trial of digital vs. film mammography showed no difference in breast cancer detection
On Sept. 16, 2005, preliminary results from a large, clinical trial of digital vs. film mammography showed no…
-
NCI-sponsored clinical trials showed patients with early-stage, HER2-positive, invasive breast cancer experienced decrease in risk of cancer recurrence
On Apr. 27, 2005, results from two large National Cancer Institute sponsored randomized clinical trials showed that patients…
-
Biotechnology | Diagnostics | Disease | NIH | Oncology | Women's Health
NCI trial reported targeted agent trastuzumab and standard chemo cut risk of HER-2-positive breast cancer
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
-
Biotechnology | Disease | FDA | Oncology | Therapeutics | Women's Health
Letrozole was approved by the FDA for the adjuvant treatment of early-stage breast cancer after five years of tamoxifen therapy
On Oct. 29, 2004, the U.S. Food and Drug Administration (FDA) approved Letrozole for the extended adjuvant treatment…
-
Biology | Diagnostics | NIH | Non-Profit Research | Oncology | Radiology | Therapeutics | Women's Health
National Cancer Institute’s Annual Report to the Nation found cancer incidence and death rates on the decline
On Jun. 3, 2004, the National Cancer Institute’s (NCI) Annual Report to the Nation found cancer incidence and…
-
World’s first use of low-dose radioactive palladium ‘seeds’ was used to treat breast cancer patients at the Women’s Research Institute in Toronto
In 2004, the world’s first use of low-dose radioactive palladium ‘seeds’ as used to treat breast cancer patients…
-
The Huntsman Cancer Center Hospital opened
On Jun. 21, 2004, the Huntsman Cancer Center Hospital was dedicated featuring a full-field digital mammography unit, a…
-
Women’s Health Initiative data showed women who take estrogen with hormone progestin have greater risk of developing breast cancer
In 2004, data from the Women’s Health Initiative (WHI) study show that women who take estrogen in combination…
